Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative ...

Ulcerative colitis (UC) is a chronic inflammatory disease of the gastrointestinal tract, which is closely related to gut barrier dysfunction. Emerging evidence shows that interleukin-22 (IL-22) ...

MedPAC's chair defended its $76 billion Medicare Advantage estimate at an insurer event. What the fight could mean for Part B premiums. Kennedy's new disclosure lists $4 million in book advances from ...

This was shown again by a brilliant study from the UK, the PROFILE trial. PROFILE compared a top-down approach with step-up ...

Targeting the gut microbiome with fecal microbiota transplantation (FMT) may help cancer patients with immunotherapy-related ...

A new drug for treating a type of inflammatory bowel disease (IBD) has been given the go-ahead by the Food and Drug Administration. On Friday, the FDA approved Pfizer’s etrasimod, branded as Velsipity ...

Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than ...

Ulcerative colitis has long been framed as a disease of overactive immunity, a condition in which the immune system attacks ...

Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown role for B cells, which ...